Methods of increasing cerebral blood flow
View Patent ↗Methods of increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or vasospasm following hemorrhagic stroke; due to chronic high blood pressure; and/or due to idiopathic causes are provided. The method for increasing blood flow in such a mammalian brain blood vessel includes administering to a patient in need thereof a therapeutically effective amount of an inhibitor of δ protein kinase C. In certain embodiments, the inhibitor can be chronically administered without causing desensitization of the patient to the inhibitor. Kits for increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or vasospasm following hemorrhagic stroke; due to chronic high blood pressure; and/or due to idiopathic causes are provided.
1. A kit comprising a peptide inhibitor of δPKC consisting of a sequence of eight contigiuous amino acid residues of SEQ ID NO:4, and instructions for use.
2. The kit of claim 1 , wherein said sequence is selected from the group consisting of SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, and SEQ ID NO:83.
3. The kit of claim 1 , further comprising a pharmaceutically acceptable carrier or vehicle.
4. The kit of claim 3 , wherein said inhibitor is mixed with said pharmaceutically acceptable carrier or vehicle.
5. A kit comprising a peptide inhibitor of δPKC consisting of a sequence of eight contiguous amino acid residues of SEQ ID NO:4, a cell-permeable carrier peptide, and instructions for use, wherein the peptide inhibitor is attached to the carrier peptide.
6. The kit of claim 5 , wherein said sequence is selected from the group consisting of SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, and SEQ ID NO:83.
7. The kit of claim 5 , wherein said carrier peptide is selected from the group consisting of a Drosophila Antennapedia homeodomain peptide, a Transactivating Regulatory Protein (Tat) peptide, and a polyarginine peptide.
8. The kit of claim 5 , wherein said carrier peptide amino acid sequence is SEQ ID NO:84.
9. The kit of claim 5 , wherein said carrier peptide amino acid sequence is SEQ ID NO:85.
10. The kit of claim 5 , further comprising a pharmaceutically acceptable carrier or vehicle.
11. The kit of claim 10 , wherein said inhibitor is mixed with said pharmaceutically acceptable carrier or vehicle.
12. A kit comprising a peptide inhibitor of δPKC consisting of a sequence of eight contiguous amino acid residues of SEQ ID NO:4 and an N-terminal Cys, a cell-permeable carrier peptide, and instructions for use, wherein the peptide inhibitor is attached to the carrier peptide.
13. The kit of claim 12 , wherein said sequence is selected from the group consisting of SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, and SEQ ID NO:83.
14. The kit of claim 12 , wherein said carrier peptide comprises an N-terminal Cys, and wherein said inhibitor is crosslinked to said carrier peptide via a Cys-Cys bond.
15. The kit of claim 12 , wherein said carrier peptide is selected from the group consisting of a Drosophila Antennapedia homeodomain peptide, a Transactivating Regulatory Protein (Tat) peptide, and a polyarginine peptide.
16. The kit of claim 15 , wherein said carrier peptide amino acid sequence is SEQ ID NO:84.
17. The kit of claim 12 , wherein said carrier peptide amino acid sequence is SEQ ID NO:85.
18. The kit of claim 12 , further comprising a pharmaceutically acceptable carrier or vehicle.
19. The kit of claim 18 , wherein said inhibitor is mixed with said pharmaceutically acceptable carrier or vehicle.